The drug does what it was designed to do. The next question is whether that matters.
No cruzamento entre genética e esperança, pesquisadores britânicos avançaram um passo significativo na longa batalha contra o Alzheimer: uma terapia chamada MAPTRx demonstrou, em testes iniciais com humanos, a capacidade de silenciar o gene responsável pela produção da proteína tau — o acúmulo silencioso que, ao longo dos anos, destrói neurônios e apaga memórias. Não é ainda uma cura, mas é a primeira vez que a ciência consegue intervir diretamente nesse mecanismo, abrindo a possibilidade de tratar a doença antes mesmo que ela se manifeste.
- A proteína tau acumula-se no cérebro por anos antes dos primeiros sintomas — e até agora nenhum tratamento aprovado conseguia tocá-la diretamente.
- Em 46 pacientes testados entre 2017 e 2020, o MAPTRx reduziu os níveis de tau em mais de 50% em apenas 24 semanas, com efeitos colaterais leves e toleráveis.
- A terapia é administrada por injeção intratecal — diretamente no canal espinhal — o que representa um desafio logístico e clínico para uso em larga escala.
- O estudo prova que o mecanismo funciona no nível molecular, mas ainda não responde se isso se traduz em benefício real para memória, cognição ou qualidade de vida.
- Ensaios de Fase 2, maiores e mais longos, já estão em andamento — deles depende a aprovação regulatória e o acesso dos pacientes ao tratamento.
Pesquisadores do Reino Unido desenvolveram uma terapia que age silenciando o gene responsável pela produção da proteína tau — substância que se acumula no cérebro de pessoas com Alzheimer e provoca a morte progressiva de neurônios. O medicamento, chamado MAPTRx ou BIIB080, é composto por pequenas moléculas que interferem na produção dessa proteína, com o objetivo de prevenir o início da doença em pessoas geneticamente predispostas ou de retardar seu avanço em quem já apresenta sintomas.
O estudo de Fase 1, conduzido pelo UCL Dementia Research Centre em Londres com apoio do NIHR UCLH Biomedical Research Centre, acompanhou 46 pacientes com média de 66 anos ao longo de três anos. Os participantes receberam diferentes doses do medicamento por injeção intratecal — uma agulha inserida no canal espinhal para alcançar o sistema nervoso central — ou placebo. Os resultados mostraram que os pacientes que receberam as duas doses mais altas apresentaram redução superior a 50% nos níveis de tau em 24 semanas. Mais de 90% toleraram bem o tratamento, com efeitos colaterais leves, sendo a dor de cabeça pós-injeção a queixa mais comum.
O que a Fase 1 estabelece é uma prova de conceito biológica: o mecanismo funciona. Mas efeito biológico não é o mesmo que benefício clínico. Saber se o MAPTRx realmente ajuda as pessoas a pensar com mais clareza, preservar memórias ou viver melhor exigirá ensaios maiores, com mais pacientes e por períodos mais longos. Esses estudos já estão em curso. Enquanto não forem concluídos e avaliados por reguladores, o medicamento permanece experimental — mas a direção, pela primeira vez, parece promissora.
Researchers in the United Kingdom have developed a therapy that appears to work by quieting the genes responsible for Alzheimer's disease and dementia. The drug, called MAPTRx, targets a protein called tau that accumulates in the brains of people with these conditions and causes the progressive death of neurons. In the first phase of human testing, published in a peer-reviewed journal, the treatment proved safe and reduced tau levels in patients' nervous systems by more than half.
The mechanism is straightforward in concept, though complex in execution. MAPTRx works by inhibiting the MAPT gene, which produces tau protein. The drug itself, known as BIIB080, consists of small molecules designed to interfere with protein production. By reducing how much tau the body makes, the therapy aims to prevent the disease from starting in people at genetic risk, or to slow its progression in those already showing symptoms. Until now, no approved treatments have directly targeted tau.
Alzheimer's is a genetic disease that causes irreversible loss of brain cells. If MAPTRx eventually reaches patients, it could offer two distinct benefits: people who carry the genetic predisposition could take it preventively, before symptoms appear, while those already experiencing cognitive decline might be able to slow the disease's advance. That possibility hinges on larger trials now underway.
The first-phase study was conducted by the UCL Dementia Research Centre in London, with support from the NIHR UCLH Biomedical Research Centre. Forty-six patients with an average age of 66 participated in testing that ran from 2017 to 2020. Researchers divided them into groups and gave different doses of the drug via intrathecal injection—a needle inserted into the spinal canal to reach the central nervous system—while others received placebo. The team then tracked tau levels in the nervous system over time.
The results were encouraging on the safety front. All patients tolerated the drug well during treatment, and more than 90 percent continued to tolerate it after treatment ended. Side effects were mild to moderate, with headache following injection being the most common complaint. More significantly, patients who received the two highest doses showed a reduction in tau protein levels exceeding 50 percent within 24 weeks of starting treatment.
These findings represent a biological proof of concept—evidence that the drug does what it was designed to do at the molecular level. But a biological effect is not the same as a clinical benefit. To know whether MAPTRx actually helps people think more clearly, remember more, or live longer, researchers will need to conduct larger trials with more patients over longer periods. Those studies are already underway. Until they are complete and the results reviewed by regulators, the drug remains experimental. What the first phase has shown is that the approach is sound, the drug is tolerable, and the mechanism works. The next question is whether that mechanism translates into something that matters in people's lives.
Notable Quotes
If the medication is approved, people with genetic predisposition could take it preventively, and those already developing the disease could reduce its progression— Study findings on potential clinical applications
The Hearth Conversation Another angle on the story
What makes this different from other Alzheimer's drugs that have failed over the years?
Most treatments have tried to clear amyloid plaques, another protein that builds up in Alzheimer's brains. This is the first to directly target tau, which is equally destructive. The fact that it actually reduced tau levels in the nervous system—not just in a test tube—is what makes it novel.
Why does it matter that they used intrathecal injection instead of a pill?
Tau lives in the central nervous system, behind the blood-brain barrier. A pill can't easily reach it. Injecting directly into the spinal fluid gets the drug where it needs to be, though it's more invasive than swallowing a tablet.
Forty-six patients seems small. How confident should we be in these results?
For phase one, it's actually a reasonable size. The goal wasn't to prove the drug works clinically—it was to prove it's safe and does what it's supposed to do biologically. Both happened. But you're right that larger trials are essential before anyone should take it.
If someone has the genetic risk, could they start taking this tomorrow?
No. It's still experimental. They'd need to be enrolled in a clinical trial. And even then, we don't know yet if preventing tau buildup actually prevents the disease from developing. That's what the next phase of testing will explore.
What happens if phase two doesn't show clinical benefit?
Then the drug stops development. A 50 percent reduction in tau is biologically interesting, but if it doesn't translate to people thinking more clearly or living better, it's not a treatment. That's the hard part of drug development—the biology has to matter in real life.